SML2728

Sigma-Aldrich

ML375

≥98% (HPLC)

Sinónimos:
ML 375, (S)-9b-(4-Chlorophenyl)-1-(3,4-difluorobenzoyl)-1,2,3,9b-tetrahydro-5H-imidazo2,1-aisoindol-5-one, VU0483253, (S)-9b-(4-Chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo2,1-aisoindol-5(9bH)-one
Empirical Formula (Hill Notation):
C23H15ClF2N2O2
Número de CAS:
Peso molecular:
424.83
MDL number:
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

α/D -150 to -175, c = 0.5 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Biochem/physiol Actions

ML375 is an orally active, brain-penetrant, potent and M5 subtype-selective muscarinic acetylcholine receptor (mAChR) negative allosteric modulator (NAM) (IC50 = 300/790 nM against 10 μM NMS-induced Ca2+ mobilization in h/r M5-transfected CHO cells; h/r M1-M4 IC50 >30 μM) that reduces N-methylscopolamine (NMS) ML5 dissociation rate without competing against NMS for receptor binding. M375 shows in vivo efficacy in rat models of substances addiction (cocaine, ethanol, oxycodone) with excellent multispecies pharmacokinetic properties.

WGK Germany

WGK 3

Flash Point F

Not applicable

Flash Point C

Not applicable

Barak W Gunter et al.
Addiction biology, 23(5), 1106-1116 (2017-10-19)
Cocaine use disorder (CUD) remains a debilitating health problem in the United States for which there are no Food and Drug Administration-approved treatment options. Accumulating anatomical and electrophysiological evidence indicates that the muscarinic acetylcholine receptor (mAChR) subtype 5 (M5 )...
Patrick R Gentry et al.
Journal of medicinal chemistry, 56(22), 9351-9355 (2013-10-30)
A functional high throughput screen and subsequent multidimensional, iterative parallel synthesis effort identified the first muscarinic acetylcholine receptor (mAChR) negative allosteric modulator (NAM) selective for the M5 subtype. ML375 is a highly selective M5 NAM with submicromolar potency (human M5...
Robert W Gould et al.
ACS chemical neuroscience, 10(8), 3740-3750 (2019-07-04)
Opioid use disorder (OUD) is a debilitating neuropsychiatric condition characterized by compulsive opioid use, dependence, and repeated relapse after periods of abstinence. Given the high risk of developing OUD following prescription opioid use, the continued need for opioid-induced analgesia, and...
Alice E Berizzi et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(7), 1510-1517 (2018-02-28)
Despite the cost to both individual and society, alcohol use disorders (AUDs) remain a major health risk within society, and both relapse and heavy drinking are still poorly controlled with current medications. Here we demonstrate for the first time that...
Alice E Berizzi et al.
Molecular pharmacology, 90(4), 427-436 (2016-07-28)
Recently, the first subtype-selective allosteric modulators of the M5 muscarinic acetylcholine receptor (mAChR) have been described, but their molecular mechanisms of action remain unknown. Using radioligand-binding and functional assays of inositol phosphate (IP) accumulation and Ca(2+) mobilization in a recombinant...

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.